Carcinoid Syndrome and Hyperinsulinemic Hypoglycemia Associated with Neuroendocrine Neoplasms: A Critical Review on Clinical and Pharmacological Management
The carcinoid syndrome (CS) and hyperinsulinemic hypoglycemia (HH) represent two of the most common clinical syndromes associated with neuroendocrine neoplasms (NENs). The former is mainly related to the serotonin secretion by a small bowel NEN, whereas the latter depends on an insulin hypersecretio...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Book |
| Published: |
MDPI AG,
2021-06-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000 am a22000003u 4500 | ||
|---|---|---|---|
| 001 | doaj_17dbd1d9dd1e4497af0fe31f6e1cf0b4 | ||
| 042 | |a dc | ||
| 100 | 1 | 0 | |a Francesca Spada |e author |
| 700 | 1 | 0 | |a Roberta E. Rossi |e author |
| 700 | 1 | 0 | |a Elda Kara |e author |
| 700 | 1 | 0 | |a Alice Laffi |e author |
| 700 | 1 | 0 | |a Sara Massironi |e author |
| 700 | 1 | 0 | |a Manila Rubino |e author |
| 700 | 1 | 0 | |a Franco Grimaldi |e author |
| 700 | 1 | 0 | |a Sherrie Bhoori |e author |
| 700 | 1 | 0 | |a Nicola Fazio |e author |
| 245 | 0 | 0 | |a Carcinoid Syndrome and Hyperinsulinemic Hypoglycemia Associated with Neuroendocrine Neoplasms: A Critical Review on Clinical and Pharmacological Management |
| 260 | |b MDPI AG, |c 2021-06-01T00:00:00Z. | ||
| 500 | |a 10.3390/ph14060539 | ||
| 500 | |a 1424-8247 | ||
| 520 | |a The carcinoid syndrome (CS) and hyperinsulinemic hypoglycemia (HH) represent two of the most common clinical syndromes associated with neuroendocrine neoplasms (NENs). The former is mainly related to the serotonin secretion by a small bowel NEN, whereas the latter depends on an insulin hypersecretion by a pancreatic insulinoma. Both syndromes/conditions can affect prognosis and quality of life of patients with NENs. They are often diagnosed late when patients become strongly symptomatic. Therefore, their early detection and management are a critical step in the clinical management of NEN patients. A dedicated and experienced multidisciplinary team with appropriate therapeutic strategies is needed and should be encouraged to optimize clinical outcomes. This review aims to critically analyze clinical features, evidence and treatment options of CS and HH and therefore to improve their management. | ||
| 546 | |a EN | ||
| 690 | |a carcinoid syndrome | ||
| 690 | |a insulinoma | ||
| 690 | |a neuroendocrine tumors | ||
| 690 | |a NENs | ||
| 690 | |a Medicine | ||
| 690 | |a R | ||
| 690 | |a Pharmacy and materia medica | ||
| 690 | |a RS1-441 | ||
| 655 | 7 | |a article |2 local | |
| 786 | 0 | |n Pharmaceuticals, Vol 14, Iss 6, p 539 (2021) | |
| 787 | 0 | |n https://www.mdpi.com/1424-8247/14/6/539 | |
| 787 | 0 | |n https://doaj.org/toc/1424-8247 | |
| 856 | 4 | 1 | |u https://doaj.org/article/17dbd1d9dd1e4497af0fe31f6e1cf0b4 |z Connect to this object online. |